Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen. “Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance … Continue reading Advocating for ROS1
I’m Janet Freeman-Daily, a cofounder of The ROS1ders. I’m writing this post in response to some of the comments we’ve seen recently in our private Facebook group “ROS1 Positive (ROS1+) Cancer.” Many of our members who have ROS1+ cancers take the targeted therapy crizotinib (Xalkori), a tyrosine kinase inhibitor (TKI). It was approved by the … Continue reading Thinking about a “drug vacation” from crizotinib? Read this first!
“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia
Read about Corinne’s journey living with ROS1 positive lung cancer. “I didn’t realize it, but I was rapidly declining, dying, in late January 2016.” ” Were you WOWed reading that, knowing that I’m still here and functioning well three years after that? I was pretty darned impressed with what medical research has made possible.”
Marisa was diagnosed with Stage IV Adenocarcinoma in October 2015 at the age of 30. Read her inspiring post about completing grad school while living with lung cancer. “On January 12th, I submitted my final assessment for grad school. Four-hundred-and-sixty-eight days following my first footsteps into the Poli Sci department at UCL. I will never … Continue reading Learning and the Passage of Time – A blog post by Marisa